| Literature DB >> 32287066 |
Christel Protiere1,2, Marion Fiorentino1,2, Abdourahmane Sow1,2, Marie Préau3, Marion Mora1,2, Lisa Fressard2,4,5, Laurence Meyer6, Jean-Daniel Lelièvre7,8,9, Olivier Lambotte10,11,12,13, Bruno Spire1,2, Marie Suzan-Monti1,2.
Abstract
: Achieving a HIV cure has become a research priority. As any improvement of knowledge, which could help scientists design new HIV cure-related clinical trials (HCRCT) depends on the risks potential participants are willing to accept, it is important to understand who will agree or refuse to participate and in which proportions. By providing insights into factors associated with reluctance toward HCRCT participation, our results may help clinicians in patient recruitment.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32287066 DOI: 10.1097/QAD.0000000000002530
Source DB: PubMed Journal: AIDS ISSN: 0269-9370 Impact factor: 4.177